



February 27, 2026

ARCALIS Completes Construction of New mRNA Drug Product Manufacturing Facility

ARCALIS, Inc. (Headquarters: Minamisoma City, Fukushima Prefecture; “ARCALIS”) today announced the completion of its new mRNA drug product manufacturing facility (“DP Facility”) in Minamisoma City, Fukushima Prefecture, on February 27, 2026.

The DP Facility operates under a quality management system aligned with international GMP standards. With the addition of this facility to ARCALIS’s Kashiwanoha Site and the Drug Substance Facility at the Minamisoma Site (completed in July 2023), ARCALIS is now positioned to provide fully integrated services spanning from research and development through commercial manufacturing of mRNA therapeutics and vaccines.

ARCALIS remains committed to delivering efficient, high-quality manufacturing solutions, and to meeting the diverse needs of its customers.

<Description>

Name	ARCALIS Minamisoma Drug Product Manufacturing Facility
Address	320-20 Kawauchisaku, Shimoota aza, Haramachi, Minamisoma, Fukushima 975-0041
Structure	Five-story steel-frame building with seismic isolation (36 meters in height)
Building Area	2,260 m ²
Total Floor Area	9,140 m ²
Facility Overview	The facility features advanced manufacturing capabilities for the production of mRNA therapeutics and vaccines. It operates under a quality management system aligned with international GMP standards, enabling supply to global markets.
Manufacturable Products	mRNA therapeutics and vaccines (LNP drug substance; liquid and lyophilized vial presentations)
Production Capability	32 million doses per year
Construction, Design, and Project Management	Obayashi Corporation

<Outside View >

